TC
LRMR icon

TFS Capital’s Larimar Therapeutics LRMR Stock Holding History

TFS Capital’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,237
Closed -$178K – 205
2017
Q2 		$178K Buy
4,237
+3,363
+385% +$172K 0.07% 472
2017
Q1 		$49K Sell
874
-780
-47% -$38.7K 0.02% 626
2016
Q4 		$63K Sell
1,654
-408
-20% -$16.5K 0.02% 671
2016
Q3 		$82K Buy
2,062
+726
+54% +$33K 0.02% 679
2016
Q2 		$96K Buy
+1,336
New +$106K 0.02% 860
2015
Q3 		– Sell
-10,385
Closed -$4.32M – 982
2015
Q2 		$4.32M Buy
10,385
+8,350
+410% +$3.49M 0.42% 44
2015
Q1 		$967K Buy
+2,035
New +$966K 0.09% 357

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

TFS Capital's LRMR Position: Q3 2017 in Review

TFS Capital sold out of Larimar Therapeutics (LRMR) in Q3 2017, closing a stake of 4,237 shares — an estimated $178K sold.

TFS Capital first reported a position in LRMR in Q1 2015 and held it in 7 quarters. The position peaked at $4.32M in Q2 2015. 62 funds tracked by Wall St. Rank hold LRMR as of Q3 2017.

  • TFS Capital reported no remaining Larimar Therapeutics position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 4,237 Larimar Therapeutics shares in Q3 2017, an estimated $178K.
  • TFS Capital first reported a position in Larimar Therapeutics in Q1 2015 and held it in 7 quarters.
  • TFS Capital's Larimar Therapeutics position peaked at $4.32M in Q2 2015.
  • 62 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.